Patent application number | Description | Published |
20110299027 | COOLING AND HEATING EYEGLASSES - Cooling and heating eyeglasses have peltier chips mounted around at least a portion of the perimeter of the lenses that provides a cooling affect that reduces eyestrain and provides cooling relief to the user. A battery pack provides the electrical energy needed to energize the peltier chips. The battery pack is connected to a neck strap that allows the user to comfortably support the batteries. In another embodiment, a plurality of smaller batteries are used and disposed within the frame eliminating the need for an external battery pack. In another embodiment, side shields are also provide with peltier chips to further control the temperature especially around the user's eyes. Because the peltier can also provide heating, a user can also select heating if preferred. The cooling and heating glasses can be used for prevention and treatment of several eye diseases and oculopathies. | 12-08-2011 |
20120066910 | ROTATING UTILITY KNIFE SCRAPER - A multi-use knife scraper has a handle portion which pivotally retains a blade holder at one end. A single-edged blade is held therein and can be positioned between a knife position which is generally parallel to the handle and a scraper position which is generally perpendicular to the handle. In one embodiment, the blade can be rotated to fit within the handle to secure the blade safely. One embodiment uses single-edged razor blades and another embodiment utilizes utility blades. The knife position allows the knife to be used as a box cutter and general purpose knife while the scraper position allows scraping and other uses where the orientation of the blade needs to be perpendicular to the handle. | 03-22-2012 |
20120101033 | RETINITIS PIGMENTOSA TREATMENT - A method of treatment of retinitis pigmentosa using a medically effective dose of insulin, IGF-1, and chlorin e6 topically applied to the conjunctival sac of the afflicted eye. The combination of these is very effective in treating retinitis pigmentosa and may be repeated as directed by a medical practitioner. The method includes preparing the dosage and filling an eye dropper with the compound, then having the patient lie in a supine position while administering the dosage. The patient remains in this position for 5 minutes to ensure absorption of the compound. In one embodiment, single use eye droppers are provided to simplify treatment. The particular dosage is adjusted to take individual metabolisms into account. A thorough examination of the patient's eyes should be done prior to treatment. | 04-26-2012 |
20120128683 | AUTISM TREATMENT - A safe and effective treatment to curtail and cure autism spectrum disorders has been described in this invention using insulin, IGF-1, with multiple known adjuvant therapeutic agents, as well as other pharmaceutical, biochemical, nurticeuticals, and biological agents or compounds delivered through the olfactory mucosal region of the nose and external auditory meatus. | 05-24-2012 |
20120156202 | AGE RELATED MACULAR DEGENERATION TREATMENT - A method for treating age related macular degeneration (AMD) using an insulin preparation applied topically to the conjunctival sac of the affected eye. Another aspect of this invention is using antiangiogenic adjuvant therapeutic agents such as bevacizumab, ranibizumab, pegaptanib, etanercept, instilled in to the afflicted eye conjunctival sac with insulin to prevent further formation of new blood vessels, and shrink the existing pathologically formed blood vessels and reduce the edema in wet AMD. This method incorporates putting the patients on low fat diet, aerobic exercise, ketamine-a NMDA blocker, reducing the blood cholesterol using adjuvant therapeutic agents selected from Statins, that are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A, (i.e. HMG-Co A) reductase which in turn reduce drusen formation that leads to AMD, combined with insulin ophthalmic drops. | 06-21-2012 |
20120157377 | METHODS TO ENHANCE NIGHT VISION AND TREATMENT OF NIGHT BLINDNESS - The invention is for a safe and effective method of administering an opthalmological therapeutic agent for the treatment of night blindness and improving night vision, using insulin, and chlorin e6, preparations instilled into the conjunctival sac as ophthalmic drops. Night blindness and decreased night vision is associated with retinal diseases such as dry age related macular degeneration, retinitis pigmentosa and other such related eye diseases by using insulin, chlorin e6, ketamine, and monoclonal antibodies and IGF-1. The ophthalmic preparations may be supplemented with oral intake of various retinal photoreceptors vision supporting lutein, vitamin A, Zeaxanthin, Omega 3 Oils and other nurticeuticals. They may also be supplemented with cholesterol lowering statins in the elderly with high blood cholesterol to prevent eye diseases such as AMD contributing to night vision and night blindness. | 06-21-2012 |
20120234331 | SNORING AND OBSTRUCTIVE SLEEP APNEA PREVENTION AND TREATMENT DEVICE - The present invention is a safe, inexpensive, easy to use and effective anti-snoring and anti-sleep apnea treatment device. The device has a vertical and horizontal bar. The horizontal bar is placed inside the mouth, behind or between the molar teeth with palatine and tongue shelves to prevent snoring and movement of the tongue backwards. The device is tethered to the hard palate by vacuum cups to prevent the movement of the tongue backwards during sleep to prevent sleep apnea. The proximal end of the vertical bar is anchored to string at the distal end with hook and loop fabric closure adhesive attachment and to the lips outside the mouth to prevent the accidental swallowing and aspiration of the device; and at the same time holds the tongue and device firmly in the mouth. The device is provided with canula with three way stopcocks to deliver supplemental oxygen and therapeutic agents. | 09-20-2012 |
20120234332 | SNORING AND OBSTRUCTIVE SLEEP APNEA PREVENTION AND TREATMENT DEVICE - A anti-snoring and anti-obstructive sleep apnea apparatus has a plate or metal frame tongue shelf splint to prevent the flaccid tongue falling back, a palate shelf splint projection to elevate the soft palate and prevents its vibration, incisors teeth receptacles or pockets sockets for jaw displacer to hold the mandible moved forwards, and to prevent it falling back held between the bite block, catheter-tubing to administer oxygen supplementation from the external source which reduces air turbulence and promotes nasal breathing, a submental suprahyoid muscle stimulator placed below the tongue, and above the mucous membrane. An injection port is provided to administer any therapeutic agents and local anesthetics to reduce the sensitivity of the tongue and oral cavity mucus membrane lining to the foreign objects. This device is used to deliver therapeutic agents to prevent and to treat halitosis and various diseases. | 09-20-2012 |
20120255561 | DEVISE FOR SNORING AND OBSTRUCTIVE SLEEP APNEA TREATMENT - A device for snoring and obstructive sleep apnea treatment has an oral elastic glove portion adapted to removably cover a free moving portion of a user's tongue. Three vacuum suction cups are used to attach the device to the hard palate and the dorsal and ventral surfaces of the tongue in order to hold the device in place without allowing the tongue to move backwards. A vacuum creating cannula and a syringe attached to a tip of the device to create a vacuum once the device in positioned in the user's mouth. In addition, a balloon is provided to prevent soft palate vibrations. A skin attachment pad is removably attached to the user's face close to the mouth and holds the end of a string provided to secure the tongue glove from moving during sleep or be accidentally swallowed. | 10-11-2012 |
20120323214 | ALZHEIMER'S DISEASE TREATMENT WITH MULTIPLE THERAPEUTIC AGENTS DELIVERED TO THE OLFACTORY REGION THROUGH A SPECIAL DELIVERY CATHETER AND IONTOPHORESIS - This invention describes the administration of multiple therapeutic agents with insulin in conjunction with bexarotene, ketamine, monoclonal antibodies Etanercept, IGF-1, and acetylcholine esterase inhibitors physostigmine, for treatment of Alzheimer's disease and other neurodegenerative diseases. Insulin, improves memory; also augments and amplifies the effects of the adjuvant therapeutic agents (paracrine and intracrine effects) and consequently reduces the β amyloid, its soluble precursors, prevents damage to the neuronal skeletal network (taupathy), and blocks glutamate excitotoxicity, reduces brain inflammation, prevents apoptosis, and increases the acetylcholine levels in the neurons and synapses; by using a combination of insulin, bexarotene, ketamine, Etanercept, IGF-1, and physostigmine therapeutic agents. The results are achieved by using the specially designed Iontophoresis incorporated olfactory mucosal delivery (ORE) catheter device located at the olfactory nerves, sphenoid sinus, and adjacent structures described here, to transport the large molecules of therapeutic agents to treat AD delivered to the CNS bypassing BBB from ORE. | 12-20-2012 |
20140012182 | ALZHEIMER'S DISEASE TREATMENT WITH MULTIPLE THERAPEUTIC AGENTS DELIVERED TO THE OLFACTORY REGION THROUGH A SPECIAL DELIVERY CATHETER AND IONTOPHORESIS - This invention describes the administration of multiple therapeutic agents with insulin in conjunction with bexarotene, ketamine, monoclonal antibodies Etanercept, IGF-1, and acetylcholine esterase inhibitors physostigmine, for treatment of Alzheimer's disease and other neurodegenerative diseases. Insulin, improves memory; also augments and amplifies the effects of the adjuvant therapeutic agents (paracrine and intracrine effects) and consequently reduces the β amyloid, its soluble precursors, prevents damage to the neuronal skeletal network (taupathy), and blocks glutamate excitotoxicity, reduces brain inflammation, prevents apoptosis, and increases the acetylcholine levels in the neurons and synapses; by using a combination of insulin, bexarotene, ketamine, Etanercept, IGF-1, and physostigmine therapeutic agents. The results are achieved by using the specially designed Iontophoresis incorporated olfactory mucosal delivery (ORE) catheter device located at the olfactory nerves, sphenoid sinus, and adjacent structures described here, to transport the large molecules of therapeutic agents to treat AD delivered to the CNS bypassing BBB from ORE. | 01-09-2014 |
20140035460 | HIGH EFFICIENCY LIGHT BULB - A high efficiency light bulb has an outer globe with a base and a detachable bulb portion. The base has a base connection portion with a screw base and a control circuit with transformer for controlling and conveying electric power from the screw base to a quartz tungsten filament. The detachable bulb portion has an outer globe and an inner globe. At least the inner globe has a transparent infrared heat reflecting coating to improve efficiency by retaining heat within and reflecting the heat back on the filament. In another embodiment, the bulb and base are not detachable and the whole bulb is replaced when it reaches the end of its usefulness. A non-reactive gas such as krypton, bromine or xenon, for example, is used to fill the bulbs. | 02-06-2014 |
20140184111 | ELECTRIC MOTOR DRIVE SYSTEM CAPTURE AND CONTROL APPARATUS FOR ENERGY SAVINGS - An electric motor drive system capture and control apparatus for energy savings has an alternating current power source electrically connected to a direct current motor. A power rectifier diode rated for the alternating current power source and the direct current motor is electrically connected in a reverse bias mode between the negative supply wire of the direct current motor and a grounded neutral conductor of the alternating current power source. A ground wire is electrically connected to the direct current motor and cross connected to a hot lag wire of the alternating current power source. The direct current motor is voltage matched to the alternating current power source. A transformer is electrically connected to the alternating current power source and the direct current motor. The system may be scaled to work with a power grid or for use in a vehicle. | 07-03-2014 |
20150073330 | ALZHEIMER'S DISEASE TREATMENT WITH MULTIPLE THERAPEUTIC AGENTS DELIVERED TO THE OLFACTORY REGION THROUGH A SPECIAL DELIVERY CATHETER AND IONTOPHORESIS - This invention describes the administration of multiple therapeutic agents with insulin in conjunction with bexarotene, ketamine, monoclonal antibodies Etanercept, IGF-1, and acetylcholine esterase inhibitors physostigmine, for treatment of Alzheimer's disease and other neurodegenerative diseases. Insulin, improves memory; also augments and amplifies the effects of the adjuvant therapeutic agents (paracrine and intracrine effects) and consequently reduces the β amyloid, its soluble precursors, prevents damage to the neuronal skeletal network (taupathy), and blocks glutamate excitotoxicity, reduces brain inflammation, prevents apoptosis, and increases the acetylcholine levels in the neurons and synapses; by using a combination of insulin, bexarotene, ketamine, Etanercept, IGF-1, and physostigmine therapeutic agents. The results are achieved by using the specially designed Iontophoresis incorporated olfactory mucosal delivery (ORE) catheter device located at the olfactory nerves, sphenoid sinus, and adjacent structures described here, to transport the large molecules of therapeutic agents to treat AD delivered to the CNS bypassing BBB from ORE. | 03-12-2015 |
20150080785 | ALZHEIMER'S DISEASE TREATMENT WITH MULTIPLE THERAPEUTIC AGENTS DELIVERED TO THE OLFACTORY REGION THROUGH A SPECIAL DELIVERY CATHETER AND IONTOPHORESIS - This invention describes the administration of multiple therapeutic agents with insulin in conjunction with bexarotene, ketamine, monoclonal antibodies Etanercept, IGF-1, and acetylcholine esterase inhibitors physostigmine, for treatment of Alzheimer's disease and other neurodegenerative diseases. Insulin, improves memory; also augments and amplifies the effects of the adjuvant therapeutic agents (paracrine and intracrine effects) and consequently reduces the β amyloid, its soluble precursors, prevents damage to the neuronal skeletal network (taupathy), and blocks glutamate excitotoxicity, reduces brain inflammation, prevents apoptosis, and increases the acetylcholine levels in the neurons and synapses; by using a combination of insulin, bexarotene, ketamine, Etanercept, IGF-1, and physostigmine therapeutic agents. The results are achieved by using the specially designed Iontophoresis incorporated olfactory mucosal delivery (ORE) catheter device located at the olfactory nerves, sphenoid sinus, and adjacent structures described here, to transport the large molecules of therapeutic agents to treat AD delivered to the CNS bypassing BBB from ORE. | 03-19-2015 |